Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for transplant patients: study aims to block dangerous late-stage virus

NCT ID NCT06958796

Recruiting now Disease control Sponsor: Camille N. Kotton, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving CytoGam® (CMV immunoglobulin) after standard antiviral treatment can prevent late CMV infection in high-risk kidney or liver transplant recipients. About 80 participants who are CMV-negative but receive an organ from a CMV-positive donor will be enrolled. The goal is to reduce the chance of serious CMV-related illness and hospitalizations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS KIDNEY TRANSPLANT; COMPLICATIONS LIVER TRANSPLANT; COMPLICATIONS ORGAN TRANSPLANT SIMULTANEOUS LIVER-KIDNEY TRANSPLANTATION; COMPLICATIONS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Texas Southwestern

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.